Changes in coagulation factors and fibrinolytic components of postmenopausal women receiving continuous hormone replacement therapy

Climacteric

Volumn 2, Issue 2, 1999, Pages 124-130

  Nozaki, M ^a   Ogata, R ^a   Koera, K ^a   Hashimoto, K ^a   Nakano, H ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Coagulation factor; Continuous regimen; Fibrinolytic components; Hormone replacement therapy; Postmenopausal women

Indexed keywords

ANTITHROMBIN III; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 7; ESTROGEN; FIBRINOGEN; FIBRINOLYTIC FACTOR; MEDROXYPROGESTERONE; PLASMINOGEN ACTIVATOR INHIBITOR; PROTEIN C; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ARTICLE; BLOOD ANALYSIS; BLOOD CLOTTING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ESTROGEN THERAPY; FEMALE; HUMAN; PATIENT CODING; POSTMENOPAUSE; PRIORITY JOURNAL; THROMBOSIS;

EID: 0032837217     PISSN: 13697137     EISSN: None     Source Type: Journal    
DOI: 10.3109/13697139909025576     Document Type: Article

References (32)

1. Stampfer MJ, Willett WC, Colditz GA, Rosner B, Speizer FE, Hennenkens CH. A prospective study of postmenopausal estrogen therapy and coronary heart disease. N Engl J Med 1985;313:1044-9
2. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991;20:47-63
3. Lobo RA. Benefits and risks of estrogen replacement therapy. Am J Obstet Gynecol 1995;173:982-9
4. Bush TL, Barrett-Connor E, Cowan LD, et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation 1987;75:1102-9
5. Hunt K, Vessey M, McPherson K, Coleman M. Long-term surveillance of mortality and cancer incidence in women receiving hormone replacement therapy. Br J Obstet Gynaecol 1987;94:620-35
6. Falkeborn M, Persson I, Adami HO, et al. The risk of acute myocardial infarction after oestrogen and oestrogen-progestogen replacement. Br J Obstet Gynaecol 1992;99:821-8
7. Psaty BM, Heckbert SR, Atkins D, et al. The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women. Arch Intern Med 1994;154:1333-9
8. Barrett-Connor E, Bush TL. Estrogen and coronary heart disease in women. J Am Med Assoc 1991;265:1861-7
9. Samaan SA, Crawford MH. Estrogen and cardiovascular function after menopause. J Am Coll Cardiol 1995;26:1403-10
10. Writing group for the PEPI trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. J Am Med Assoc 1995;273:199-208
11. Inman WH, Vessey MP, Westerholm B, Engelund A. Thromboembolic diseases and the steroidal content of oral contraceptives: a report to the Committee on Safety of Drugs. Br Med J 1970;2:203
12. Mann JI, Vessey MP, Thorogood M, Doll R. Myocardial infarction in young women with special reference to oral contraceptive practice. Br Med J 1975;2:241
13. Bottinger LD, Boman G, Eklund G, Westerholm B. Oral contraceptives and thromboembolic disease: effects of lowering estrogen content. Lancet 1980;1:1097
14. Meade TW, Greenberg G, Thompson SG. Progestogens and cardiovascular reactions associated with oral contraceptives and a comparison of the safety of 50- and 30-μg oestrogen preparations. Br Med J 1980;280:1157
15. Notelovitz M, Kitchens C, Coone L, McKenzie L, Carter R. Low-dose oral contraceptive usage and coagulation. Am J Obstet Gynecol 1981;141:71-5
16. Heinemann LAJ, Lewis MA, Thorogood M, Spitzer WO, Guggenmoos-Holzmann I, Bruppacher R. The transnational research group on oral contraceptives and the health of young women. Case-control study of oral contraceptives and risk of thromboembolic stroke: results from international study on oral contraceptives and health of young women. Br Med J 1997;315:1502-4
17. Dari F, Barthels M, Conard J, et al. Multicenter evaluation of a chromogenic substrate method for photometric determination of prothrombin time. Thromb Haemost 1987;58:856-65
18. Exner T, Burridge J, Power P, Rickard KA. An evaluation of currently available methods for plasma fibrinogen. Am J Clin Pathol 1979;71:521-7
19. Vinazzer H, Pangraz U. Protein C: comparison of different assays in normal and abnormal plasma samples. Thromb Res 1987;46:1-8
20. Bergsdorf N, Nilsson T, Wallen P. An enzyme linked immunosorbent assay for determination of tissue plasminogen activator applied to patients with thromboembolic disease. Thromb Haemost 1983;50:740-4
21. Philips M, Juul AG, Selmer J, Lind B, Thorsen S. A specific immunologic assay for functional plasminogen activator inhibitor 1 in plasma: standardized measurements of the inhibitor and related parameters in patients with venous thromboembolic disease. Thromb Haemost 1992;68:486-94
22. Fossati P, Prencipe L. Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. Clin Chem 1982;28:2077-80
23. Dickson WJ, Jennrich R. Stepwise regression 2R. In BMDP Statistical Software Manual. Berkeley: University of California Press, 1990:359-94
24. Lobo RA. Estrogen and the risk of coagulopathy. Am J Med 1992;92:283-5
25. Mashchak CA, Lobo RA, Dozono-Takano R, et al. Comparison of pharmacodynamic properties of various estrogen formulations. Am J Obstet Gynecol 1982;144:311-18
26. Green D, Chamberlain MA, Ruth KJ, Folsom AR, Liu K. Factor VII, cholesterol and triglycerides. The CARDIA Study. (Coronary Artery Risk Development in Young Adults Study.) Arterioscler Thromb Vasc Biol 1997;17:51-5
27. Tikkanen MJ. The menopause and hormone replacement therapy: lipids, lipoproteins, coagulation and fibrinolytic factors. Maturitas 1996;23:209-16
28. Nabulsi AA, Folsom AR, White A, et al. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. N Engl J Med 1993;328:1069-75
29. Thom M, Dubiel M, Kakkar VV, Studd JWW. The effect of different regimens of oestrogens on the clotting and fibrinolytic system of the postmenopausal woman. Front Horm Res 1978;5:192-202
30. Notelovitz M, Kitchens C, Ware M, Hirschburg K, Coone L. Combination estrogen and progestogen replacement therapy does not adversely affect coagulation. Obstet Gynecol 1983;62:596-600
31. The writing group for the Estradiol Clotting Factors Study. Effects on haemostasis of hormone replacement therapy with transdermal double-blind, placebo-controlled study. Thromb Haemost 1996;75:476-80
32. Sporrong T, Mattsson LA, Samsioe G, Stigendal L, Hellgren M. Haemostatic changes during continuous oestradiol-progestogen treatment of postmenopausal women. Br J Obstet Gynaecol 1990;97:939-44